Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Other Non-Current Liabilities (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Other Non-Current Liabilities for 2 consecutive years, with $12.3 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 118.19% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, up 118.19% year-over-year, with the annual reading at $12.3 million for FY2025, 118.19% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $12.3 million at NRX Pharmaceuticals, down from $15.9 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $16.3 million in Q2 2025, with the low at $8000.0 in Q2 2024.